 |
|
HEALTH CARE REFORM
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
Isabelle Pitrou, MD, MSc;
Isabelle Boutron, MD, PhD;
Nizar Ahmad, MD, MSc;
Philippe Ravaud, MD, PhD
Arch Intern Med. 2009;169(19):1756-1761.
Background Reports of clinical trials usually emphasize efficacy results, especially when results are statistically significant. Poor safety reporting can lead to misinterpretation and inadequate conclusions about the interventions assessed. Our aim was to describe the reporting of harm-related results from randomized controlled trials (RCTs).
Methods We searched the MEDLINE database for reports of RCTs published from January 1, 2006, through January 1, 2007, in 6 general medical journals with a high impact factor. Data were extracted by use of a standardized form to appraise the presentation of safety results in text and tables.
Results Adverse events were mentioned in 88.7% of the 133 reports. No information on severe adverse events and withdrawal of patients owing to an adverse event was given in 27.1% and 47.4% of articles, respectively. Restrictions in the reporting of harm-related data were noted in 43 articles (32.3%) with a description of the most common adverse events only (n = 17), severe adverse events only (n = 16), statistically significant events only (n = 5), and a combination of restrictions (n = 5). The population considered for safety analysis was clearly reported in 65.6% of articles.
Conclusion Our review reveals important heterogeneity and variability in the reporting of harm-related results in publications of RCTs.
Author Affiliations: Département d’Epidémiologie, Biostatistique, et Recherche Clinique, Groupe Hospitalier Bichat-Claude Bernard (AP-HP); Université Denis Diderot; INSERM U738, Paris, France.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Adverse Events in Randomized Trials: Neglected, Restricted, Distorted, and Silenced
John P. A. Ioannidis
Arch Intern Med. 2009;169(19):1737-1739.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Dabigatran: Do We Have Sufficient Data?: Comment on "Dabigatran Association With Higher Risk of Acute Coronary Events"
Jacobs and Stessman
Arch Intern Med 2012;0:archinternmed.2011.1721v1-8.
FULL TEXT
Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations
Hammad et al.
Clin Trials 2011;8:559-570.
ABSTRACT
| FULL TEXT
Rhetorical Techniques Used in the Reporting of Cardiac Resynchronization Trials
Wilson
Arch Intern Med 2011;171:1500-1502.
FULL TEXT
Principles of Conservative Prescribing
Schiff et al.
Arch Intern Med 2011;171:1433-1440.
ABSTRACT
| FULL TEXT
Rates of Treatment Discontinuation Due to Adverse Events for Echinocandins
Muller et al.
Antimicrob. Agents Chemother. 2011;55:3643-3644.
FULL TEXT
The Year in Epidemiology, Health Services Research, and Outcomes Research
Hlatky and Heidenreich
J Am Coll Cardiol 2011;57:1859-1866.
FULL TEXT
Antiplatelet Therapy for Every Diabetic Person?
Nicolucci and Standl
Diabetes Care 2011;34:S150-S154.
FULL TEXT
Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources
Loke et al.
Therapeutic Advances in Drug Safety 2011;2:59-68.
ABSTRACT
From Quality of Publication to Quality of Care: Translating Trials to Practice
Dancey
JNCI J Natl Cancer Inst 2010;102:670-671.
FULL TEXT
Adverse effects of treatment in randomised controlled trials are variably and inconsistently reported
Nuovo
Evid. Based Med. 2010;15:60-60.
FULL TEXT
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
Moher et al.
BMJ 2010;340:c869-c869.
FULL TEXT
Characteristics of Published Comparative Effectiveness Studies of Medications
Hochman and McCormick
JAMA 2010;303:951-958.
ABSTRACT
| FULL TEXT
Adverse Events in Randomized Trials: Neglected, Restricted, Distorted, and Silenced
Ioannidis
Arch Intern Med 2009;169:1737-1739.
FULL TEXT
|
